Back to Jefferies Financial Group Inc. Jefferies Financial Group Inc.

PTGXPTGX
Showing 7 of 14 quarters

Position history for Jefferies Financial Group Inc.Jefferies Financial Group Inc.'s holdings in PROTAGONIST THERAPEUTICS INC

No. Jefferies Financial Group exited its PTGX (Protagonist Therapeutics) position in Q1 2026. Its Q4 2025 13F listed 5,000 shares worth $436,700. Jefferies Financial Group first reported PTGX in Q4 2022 and held it in 12 quarterly 13F filings.

Final Value

$0

Final Shares

0

Total Value Change

-$81.7M

Total Shares Change

-1.8M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q1
Latest
Exited
0
-100.0%
$00.0%$105.40
0
2025-Q4
Decreased
5,000
-99.4%
$436,7000.0%$87.34
0
2025-Q3
Decreased
821,503
-0.3%
$54.6M0.3%$66.43
0
2025-Q2
Increased
824,019
+30.4%
$45.5M0.4%$55.27
44
2025-Q1
Decreased
631,893
-57.6%
$30.6M0.3%$48.36
0
2024-Q4
Decreased
1.5M
-17.9%
$57.5M0.3%$38.60
0
2024-Q3
Decreased
1.8M
-11.1%
$81.7M0.6%$45.00
0

Other major holders of PTGX: BlackRock, Inc., FARALLON CAPITAL MANAGEMENT, L.L.C.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used